Background
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that primarily affects motor function but also concerns extramotor systems. The degeneration of the motor system typically involves both upper motor neurons, located in the primary motor cortex, and lower motor neurons from the brainstem nuclei and anterior horns of the spinal cord. The disease has a uniformly fatal outcome as a result of muscle weakness, with median survival of 2-4 years [
1]. The underlying pathophysiology is poorly understood, and effective treatments are still needed for this neurodegenerative disease.
There is increasing awareness that ALS is a clinically heterogeneous disease [
2]. There is also a general recognition that ALS patients commonly present deficits not only in executive functions but also memory [
3,
4] and social cognition with impairment of both cognitive and affective theory of mind [
5‐
7].
Magnetic resonance imaging (MRI) of the brain and spinal cord is routinely used in the diagnostic work-up of ALS, to rule out various pathological conditions that may masquerade as motor neuron disease, but rarely gives specific clues to the positive diagnosis. Automated techniques for analysing MRI images have been developed notably with statistical parametric mapping (SPM) software to carry out voxel-by-voxel analysis of the whole brain (voxel-based morphometry (VBM)). Most of the studies, have reported extensive grey matter (GM) atrophy, not confined to motor areas [
8].
Positron emission tomography (PET) combined with
18F-fluorodeoxyglucose (FDG), a specific radiotracer for glucose metabolism, indicates glucose uptake by astrocytes and neurons [
9] and reveals local brain activity. Early studies found reduced regional cerebral glucose utilization in patients with ALS [
10], mostly in the frontal cortex but also in other cortical territories such as the superior occipital cortex [
11]. More recently, other authors, adopting a voxel-by-voxel approach [
12‐
16], have observed severe hypometabolism in the premotor cortex, postcentral gyrus, prefrontal cortex, lingual gyrus, fusiform gyrus and thalamus. They also observed an increased cerebral glucose metabolism or hypermetabolism in the medial temporal lobe, cerebellum, occipital cortex and brainstem. This hypermetabolism has been proposed as a possible biomarker for ALS by Pagani and colleagues [
13]. It is not yet known, however, whether it reflects a compensatory mechanism in the brain or deleterious metabolic activity. Nevertheless, it is important to note that the limited PET camera resolution can give rise to partial volume effects (PVEs) that result in blurring and, therefore, an underestimation of regional activity, particularly in small structures or those with volume loss. Since previous FDG-PET studies did not correct for PVEs, the metabolic abnormalities observed in patients with ALS have to be interpreted cautiously.
The abovementioned studies investigated different groups of non-demented patients with ALS using either brain MRI or FDG-PET (without correction for PVEs). Only one combined these two techniques in a single group of 18 patients with ALS who met the Neary criteria for frontotemporal dementia (FTD) [
17]. The authors assessed brain GM structural changes using VBM and metabolic changes using FDG-PET. They concluded that the metabolic changes corresponded to the structural changes, with a few exceptions.
To our knowledge, no combined assessment of GM volume and regional cerebral metabolism has yet been carried out in non-demented patients with ALS. The goals of the present study were threefold: (1) determine both GM volume and glucose metabolism changes in a sample of patients with ALS by adopting a voxel-based approach; (2) further study the clinical significance of hypermetabolism by assessing its relationship with selected cognitive scores; and (3) carry out a direct voxelwise comparison of the degrees of local GM atrophy and hypometabolism throughout the brain by using a specific processing technique developed in our laboratory that has already been applied in early Alzheimer’s disease [
18], alcoholism [
19] and the behavioural variant of FTD [
20].
Discussion
To our knowledge, this was the first neuroimaging study to closely examine the relationship between cerebral GM volume and glucose metabolism via a direct comparison of both parameters, as well as the relationship between hypermetabolism and cognitive performance in patients with ALS. We first compared GM volume and cerebral glucose metabolism in patients versus controls. We found (1) marked GM atrophy not only in the right premotor cortex but also in extramotor regions, (2) glucose hypometabolism mainly in both the thalamus and parietal lobe and (3) glucose hypermetabolism located bilaterally in the cerebellar vermis, medial temporal lobe and fusiform gyrus. We then extracted the metabolic values of the main hypermetabolic clusters and correlated them with cognitive scores that were expected to depend on these brain regions. We found only negative correlations: first, between the hippocampus and left parahippocampus and episodic memory and second, between the left fusiform gyrus and cognitive theory of mind. We also conducted a voxelwise comparison of the degrees of local atrophy and hypometabolism, using a method specially designed for this purpose, and we observed that GM atrophy predominated in the bilateral middle temporal pole and left hippocampus, while hypometabolism predominated in a single cluster located in the left superior medial frontal cortex.
Between-group comparisons
The profile of GM atrophy in our patients was in agreement with previous studies that had reported motor and extramotor GM atrophy in a parietotemporal network [
42‐
49], as well as the putamen [
44,
50‐
52].
The pathological involvement of the putamen in ALS may seem surprising, as patients do not typically exhibit extrapyramidal signs. However, ubiquitin immunoreactive intracytoplasmic inclusions and neuronal loss have been found in the striatonigral system in half of patients with classic motor neuron disease [
53]. Interestingly, in the study of Kim et al., the putamen was among the most atrophied brain regions in cognitively impaired ALS patients [
52]. Furthermore, the putamen has a major role in verbal fluency, working memory and speech production [
54], cognitive domains frequently impaired in ALS [
55]. Finally, putaminal regions receive afferences from the motor and premotor cortices [
51], all of which being heavily affected in this study.
Concerning the hypometabolism, our results are in line with most previous studies [
12‐
14,
16]. Concerning the hypometabolism in the paracentral lobule, this result has rarely been found with
18FDG-PET. Kew et al., using C
15O
2 in 12 patients with ALS, observed a significant reduction of cerebral blood flow at rest within this structure [
56]. Concerning the decreased uptake of
18FDG within the left inferior parietal gyrus found in our sample of patients, PET studies using [
11C]-flumazenil, or C
15O
2 [
56‐
58], also found reduced regional cerebral blood flow within the parietal lobe. We also found significantly lower frontal metabolism (superior medial) in our patient group that is in line with the fact that they present frontal dysfunction. A study went further showing that prefrontal hypometabolism was associated with reduced clinical functioning in ALS patients [
14]. Decreased glucose uptake in the thalamus has also been reported by Cistaro et al. and is thought to be a metabolic signature of
C9orf72-related ALS [
59]. Up to 10% of patients with ALS have a mutated gene; the most common of which is
C9orf72. In patients with this mutation, the thalamic hypometabolism is slightly more marked than it is in sporadic ALS cases [
14].
Our results confirm the brain hypermetabolism in ALS already demonstrated in previous studies [
12‐
14,
16]. Concerning the brain regions that were found to exhibit increased glucose metabolism, results were mainly in agreement with previous studies that also observed increased glucose metabolism in the medial temporal lobe and cerebellum [
13,
14].
Negative correlations with episodic memory and cognitive theory of mind
We observed significant negative correlations between episodic memory (immediate recall) and the metabolic value of the right hippocampus, the left hippocampus and the left parahippocampal gyrus. We also found negative correlations between metabolic activity within the left fusiform gyrus and cognitive theory of mind. The negative correlation between metabolism and cognitive scores means that hypermetabolism is associated with a functional deficiency of the involved brain area. Indeed, given that our patients with ALS scored more poorly than controls for episodic memory as well as for cognitive theory of mind, this result indicates that the abnormal pattern of glucose metabolism within these regions was not associated with preserved performances. This result was not expected because generally, when studies found hypermetabolism or hyperactivation, it is usually considered as the reflection of compensatory mechanisms [
60,
61]. However, within the framework of Huntington’s disease, a previous work has shown a link between hyperactivation of the precuneus and impaired performances of motor sequence learning [
62]. In ALS, it has been suggested that cerebral hypermetabolism reflects neuroinflammation, characterized by activated astrocytes and microglia [
16], rather than compensatory neuronal activity. Neuroinflammation has a deleterious effect and is therefore more consistent with the negative correlations we found in our patients between metabolic data and relevant cognitive scores.
This finding further highlights the potential role of cerebral hypermetabolism as a functional imaging marker for ALS.
Voxelwise comparisons between alterations
This analysis revealed differences in the relative degrees of GM atrophy and cerebral glucose hypometabolism.
Atrophy was greater than hypometabolism in two main regions: the temporal lobe (anterior, lateral and medial) and the calcarine sulcus. Based on previous studies carried out in Alzheimer’s disease, frontotemporal dementia or chronic alcoholism [
18,
20,
63,
64], it is generally thought that loss of brain cells other than neurons might result in atrophy without associated hypometabolism. In ALS, an increasing number of studies have suggested that astrocytosis and/or microglial activation could be involved in the pathophysiology of the disease [
65,
66].
The finding of a normal, i.e. higher than expected, level of glucose metabolism in atrophic cerebral zones may also suggest that compensatory mechanisms are at work in these structures, helping to maintain a moderately high metabolic level relative to structural alterations—a hypothesis previously developed for Alzheimer’s disease [
18]. In this disease, according to the authors, the presence of abnormally phosphorylated tau proteins that aggregates to form neurofibrillary tangles may be one of the processes underlying severe atrophy and moderate hypometabolism in the hippocampus. In ALS, TDP-43 inclusions are located in neurons and astrocytes of ALS patients, not only in the motor regions but also in the temporal lobe [
67]. Following the same reasoning, the presence of TDP-43 could lead to a massive neuronal loss, whereas moderate hypometabolism could be explained by a compensation of the remaining neurons.
We found that hypometabolism was more severe than atrophy in the left superior medial frontal cortex. This result suggests that ALS is characterized by genuine functional alterations (metabolic, chemical or molecular) on top of the neuronal loss, heightening the functional consequences of local GM atrophy. Supporting the notion of metabolic alterations in ALS, a study used the benzodiazepine GABA
A marker
11C-flumazenil to study brain dysfunction in 17 patients [
58]. Flumazenil is an antagonist at the benzodiazepine subunit of the GABA
A receptor. These authors found reduced binding of
11C-flumazenil in the dorsomedial prefrontal cortex notably. This may reflect the downregulation of postsynaptic GABA
A receptor expression [
58]. Given that glucose metabolism reflects synaptic activity [
68], the detrimental effects of ALS on neurotransmission systems could explain why metabolic dysfunction precedes GM atrophy (e.g. within the frontal lobe). Greater hypometabolism than GM atrophy has also been observed in the behavioural variant of FTD [
20], suggesting that this could be a remote effect of GM atrophy on metabolism, or a diaschisis.
Diaschisis refers to a change in the metabolic activity of neurons that are anatomically or functionally connected to a damaged area. The medial prefrontal cortex is connected to limbic structures such as the medial temporal lobe and putamen [
69]. The neuronal loss reflected by GM atrophy within the temporal lobe and putamen (see above) may remotely affect the metabolism of the medial prefrontal cortex, though possibly only for a limited period of time, as disconnected neurons eventually die, giving rise to different patterns of brain volume and metabolic impairment.
The study has some limitations. The major one is the existence of two groups of healthy subjects. Indeed, as our protocol did not include the neuroimaging examinations for healthy subjects, we used the scans of healthy subjects of another protocol of our laboratory. Then, the threshold that we used in this article is relatively liberal even if it has been employed in several MRI [
45,
49,
70‐
75] or PET studies [
14,
16] in ALS. However, with a more stringent threshold, we could have missed some interesting findings. Finally, this study should be replicated in a bigger group of ALS patients.
Conclusions
Taken together, our results confirm the existence of structural and metabolic changes in the brains of patients with ALS without dementia. We found that regional cerebral hypermetabolism is associated to impaired cognitive performance, which suggests that it reflects a local deleterious neuronal and/or astrocytic process. Our findings also emphasize the complex relationships between GM atrophy and hypometabolism, and the regional heterogeneity in their hierarchy. Greater GM atrophy than hypometabolism might mean either that brain tissue loss does not involve metabolically active cells or that the metabolism of the remaining cells is higher than expected. Greater hypometabolism than GM atrophy could reflect either a disconnection mechanism or an early stage of metabolic neuronal failure preceding cell death. Longitudinal studies are warranted to take account of the potential lapse between the different pathological processes.
Acknowledgements
The authors are grateful to B. Landeau and R. La Joie for their contribution and the Cyceron MRI-PET staff members (C. Lebouleux, M.H. Noel and M.C. Onfroy) for their help with patients and imaging examination acquisition. The authors also wanted to thank S. Segobin for his valuable advices during the revision phase.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (
http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.